10月8日，石药集团盘中下跌3.01%，报9.52港元，成交额3.76亿港元。消息面上，公司日前宣布8项肿瘤临床试验进展将于10月底ESMO年会发布，但创新药板块整体走弱，港股制药股多数下跌，石药集团随板块回调。
参考行业表现，中国生物制药跌1.85%，翰森制药跌2.42%，和黄医药跌1.07%，行业情绪偏谨慎。此前石药集团接连披露多项研发进展，市场关注ESMO临床数据兑现情况，但近期海外利率预期反复令创新药估值承压。
石药集团有限公司主要从事药品生产及销售，业务涵盖成药、原料产品、功能食品等，产品覆盖神经系统、抗肿瘤、抗感染、心血管等领域，销往国内外市场。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.